Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quarfloxacin in relapsed/refractory B-CLL
NCT00485966Phase 2Withdrawn
- Sponsor
- Cylene Pharmaceuticals
- Start
- Jun 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of quarfloxin in chronic lymphocytic leukemia (CLL), sponsored by Cylene Pharmaceuticals. Primary endpoints: Efficacy and Safety. Planned start Jun 2007; status: withdrawn.
02
Drugs
quarfloxin
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT00485966.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00485966.